Compare MLP & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLP | DCTH |
|---|---|---|
| Founded | 1909 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.5M | 311.7M |
| IPO Year | 2010 | 2015 |
| Metric | MLP | DCTH |
|---|---|---|
| Price | $15.91 | $10.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | 16.5K | ★ 272.1K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.53 |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $19,457,000.00 | N/A |
| Revenue This Year | N/A | $24.54 |
| Revenue Next Year | N/A | $33.15 |
| P/E Ratio | ★ N/A | $155.43 |
| Revenue Growth | ★ 68.24 | N/A |
| 52 Week Low | $13.84 | $8.12 |
| 52 Week High | $20.34 | $18.23 |
| Indicator | MLP | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 50.69 | 73.40 |
| Support Level | $15.75 | $10.50 |
| Resistance Level | $16.48 | $11.25 |
| Average True Range (ATR) | 0.38 | 0.32 |
| MACD | 0.08 | 0.18 |
| Stochastic Oscillator | 57.84 | 92.58 |
Maui Land & Pineapple Co Inc is a landholding and operating parent company that owns land and commercial property on the island of Maui, Hawaii. The Company puts its assets into productive use by planning, managing, developing, and selling residential, resort, commercial, agricultural, and industrial real estate. Its segments include land development and sales, which cover land planning, entitlement, development, construction, and sales of land assets; leasing, which generates revenue from real property leasing, license fees and royalties, and includes maintenance of real estate assets, conservation activities, and management of water systems in West and Upcountry Maui; and resort amenities, which include a membership program offering benefits within the Kapalua Resort.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.